+关注
徐军1983
暂无个人介绍
IP属地:浙江
13
关注
0
粉丝
0
主题
0
勋章
主贴
热门
徐军1983
05-16
$Faraday Future(FFIE)$
老美论坛上都在传,搞到10美金!
徐军1983
06-06
$蔚来(NIO)$
今天看不起蔚来 明天让你高攀不起!蔚来稳定2万+,乐道1万+, 年底股价必上30!
徐军1983
06-03
$(FFIE)$
重新起飞,破5美刀
徐军1983
05-30
$(NIO)$
2024业绩爆表!看涨20元!
徐军1983
05-17
$Faraday Future(FFIE)$
徐军1983
05-31
$Faraday Future(FFIE)$
坚持持有,10美刀见!
徐军1983
05-17
$Faraday Future(FFIE)$
FF的春天才刚开的,拿住了,10美金见!
徐军1983
10-10
优秀
辉瑞公司的抗癌药物组合在晚期研究中提高了总生存率
徐军1983
10-01
$小鹏汽车(XPEV)$
重新站上50元!指日可待!
徐军1983
06-12
$(AAPL)$
继续涨 加油
徐军1983
06-01
$(NIO)$
看涨20美刀!
徐军1983
05-16
$Faraday Future(FFIE)$
10刀见
去老虎APP查看更多动态
{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3556860555840528","uuid":"3556860555840528","gmtCreate":1593766533074,"gmtModify":1684307967425,"name":"徐军1983","pinyin":"xj1983xujun1983","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/3c71435fdb1d7cf5b4939778f4e8ecfe","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":13,"tweetSize":12,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖(非转发)","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":1,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-3","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"偶像虎友","description":"加入老虎社区1500天","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.08.12","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"228c86a078844d74991fff2b7ab2428d-3","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资合伙人虎","description":"证券账户累计交易金额达到100万美元","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.08.02","exceedPercentage":"93.45%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.07.12","exceedPercentage":"93.95%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.06.29","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.06.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":9,"crmLevelSwitch":0,"location":"浙江","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":358521982963944,"gmtCreate":1728570071465,"gmtModify":1728570073289,"author":{"id":"3556860555840528","authorId":"3556860555840528","name":"徐军1983","avatar":"https://static.tigerbbs.com/3c71435fdb1d7cf5b4939778f4e8ecfe","crmLevel":9,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3556860555840528","authorIdStr":"3556860555840528"},"themes":[],"htmlText":"优秀","listText":"优秀","text":"优秀","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/358521982963944","repostId":"2474492713","repostType":2,"repost":{"id":"2474492713","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1728557104,"share":"https://www.laohu8.com/m/news/2474492713?lang=&edition=full","pubTime":"2024-10-10 18:45","market":"us","language":"zh","title":"辉瑞公司的抗癌药物组合在晚期研究中提高了总生存率","url":"https://stock-news.laohu8.com/highlight/detail?id=2474492713","media":"Reuters","summary":" 路透10月10日 - 辉瑞 周四称,在一项晚期研究中,其药物Talzenna和Xtandi的组合有助于延长一种晚期前列腺癌患者的生命。辉瑞公司说,与Xtandi单药相比,这种联合用药在转移性抗性前列腺癌 患者的总生存期方面有明显改善,无论是否存在基因突变。据辉瑞公司称,约有10%-20%的前列腺癌患者会在确诊后5到7年内患上mCRPC。辉瑞表示,它计划与全球卫生机构分享研究结果,以便更新Talzenna的标签。","content":"<html><body><p>((自动化翻译由路透提供,请见免责声明 ))</p><p> 路透10月10日 - <a href=\"https://laohu8.com/S/PFE\">辉瑞</a> 周四称,在一项晚期研究中,其药物Talzenna和Xtandi的组合有助于延长一种晚期前列腺癌患者的生命。</p><p>辉瑞公司说,与Xtandi单药相比,这种联合用药在转移性抗性前列腺癌(mCRPC) 患者的总生存期方面有明显改善,无论是否存在基因突变。 </p><p>总生存期是指患者在确诊或开始治疗后的生存时间。</p><p>mCRPC是一种癌症已扩散到身体其他部位的晚期疾病,通常预后较差。据辉瑞公司称,约有10%-20%的前列腺癌患者会在确诊后5到7年内患上mCRPC。 </p><p>Talzenna-Xtandi组合去年获得美国食品药品管理局批准 (link),用于治疗有一种基因突变的mCRPC患者。</p><p>辉瑞表示,它计划与全球卫生机构分享研究结果,以便更新Talzenna的标签。</p><p>美国食品和药物管理局去年还批准了 (link) <a href=\"https://laohu8.com/S/AZN\">阿斯利康</a>公司的Lynparza与激素疗法阿比特龙联用,治疗有一种基因突变的mCRPC患者。 </p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>辉瑞公司的抗癌药物组合在晚期研究中提高了总生存率</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n辉瑞公司的抗癌药物组合在晚期研究中提高了总生存率\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2024-10-10 18:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>((自动化翻译由路透提供,请见免责声明 ))</p><p> 路透10月10日 - <a href=\"https://laohu8.com/S/PFE\">辉瑞</a> 周四称,在一项晚期研究中,其药物Talzenna和Xtandi的组合有助于延长一种晚期前列腺癌患者的生命。</p><p>辉瑞公司说,与Xtandi单药相比,这种联合用药在转移性抗性前列腺癌(mCRPC) 患者的总生存期方面有明显改善,无论是否存在基因突变。 </p><p>总生存期是指患者在确诊或开始治疗后的生存时间。</p><p>mCRPC是一种癌症已扩散到身体其他部位的晚期疾病,通常预后较差。据辉瑞公司称,约有10%-20%的前列腺癌患者会在确诊后5到7年内患上mCRPC。 </p><p>Talzenna-Xtandi组合去年获得美国食品药品管理局批准 (link),用于治疗有一种基因突变的mCRPC患者。</p><p>辉瑞表示,它计划与全球卫生机构分享研究结果,以便更新Talzenna的标签。</p><p>美国食品和药物管理局去年还批准了 (link) <a href=\"https://laohu8.com/S/AZN\">阿斯利康</a>公司的Lynparza与激素疗法阿比特龙联用,治疗有一种基因突变的mCRPC患者。 </p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SG9999002232.USD":"Allianz Global High Payout USD","BK4007":"制药","LU0234572021.USD":"高盛美国核心股票组合Acc","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","PFE":"辉瑞","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","LU0058720904.USD":"联博国际健康护理基金A","SG9999002224.SGD":"Allianz Global High Payout SGD","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","BK4550":"红杉资本持仓","BK4588":"碎股","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","BK4568":"美国抗疫概念","LU0122379950.USD":"贝莱德世界健康科学A2","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","BK4581":"高盛持仓","SG9999001176.USD":"United Global Healthcare Acc USD","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY \"A\" (USD) ACC","LU1883839398.USD":"AMUNDI FUNDS INCOME OPPORTUNITIES \"A2\" (USD) ACC","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","BK4592":"伊斯兰概念","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","BK4533":"AQR资本管理(全球第二大对冲基金)"},"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2474492713","content_text":"((自动化翻译由路透提供,请见免责声明 )) 路透10月10日 - 辉瑞 周四称,在一项晚期研究中,其药物Talzenna和Xtandi的组合有助于延长一种晚期前列腺癌患者的生命。辉瑞公司说,与Xtandi单药相比,这种联合用药在转移性抗性前列腺癌(mCRPC) 患者的总生存期方面有明显改善,无论是否存在基因突变。 总生存期是指患者在确诊或开始治疗后的生存时间。mCRPC是一种癌症已扩散到身体其他部位的晚期疾病,通常预后较差。据辉瑞公司称,约有10%-20%的前列腺癌患者会在确诊后5到7年内患上mCRPC。 Talzenna-Xtandi组合去年获得美国食品药品管理局批准 (link),用于治疗有一种基因突变的mCRPC患者。辉瑞表示,它计划与全球卫生机构分享研究结果,以便更新Talzenna的标签。美国食品和药物管理局去年还批准了 (link) 阿斯利康公司的Lynparza与激素疗法阿比特龙联用,治疗有一种基因突变的mCRPC患者。","news_type":1},"isVote":1,"tweetType":1,"viewCount":88,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":355430951645464,"gmtCreate":1727777110090,"gmtModify":1727777111357,"author":{"id":"3556860555840528","authorId":"3556860555840528","name":"徐军1983","avatar":"https://static.tigerbbs.com/3c71435fdb1d7cf5b4939778f4e8ecfe","crmLevel":9,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3556860555840528","authorIdStr":"3556860555840528"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/XPEV\">$小鹏汽车(XPEV)$ </a> 重新站上50元!指日可待!","listText":"<a href=\"https://laohu8.com/S/XPEV\">$小鹏汽车(XPEV)$ </a> 重新站上50元!指日可待!","text":"$小鹏汽车(XPEV)$ 重新站上50元!指日可待!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/355430951645464","isVote":1,"tweetType":1,"viewCount":607,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":315808304271584,"gmtCreate":1718132577210,"gmtModify":1718132578485,"author":{"id":"3556860555840528","authorId":"3556860555840528","name":"徐军1983","avatar":"https://static.tigerbbs.com/3c71435fdb1d7cf5b4939778f4e8ecfe","crmLevel":9,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3556860555840528","authorIdStr":"3556860555840528"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AAPL\">$(AAPL)$ </a><v-v data-views=\"1\"></v-v> 继续涨 加油","listText":"<a href=\"https://laohu8.com/S/AAPL\">$(AAPL)$ </a><v-v data-views=\"1\"></v-v> 继续涨 加油","text":"$(AAPL)$ 继续涨 加油","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/315808304271584","isVote":1,"tweetType":1,"viewCount":420,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":313998368497744,"gmtCreate":1717680101499,"gmtModify":1717680103442,"author":{"id":"3556860555840528","authorId":"3556860555840528","name":"徐军1983","avatar":"https://static.tigerbbs.com/3c71435fdb1d7cf5b4939778f4e8ecfe","crmLevel":9,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3556860555840528","authorIdStr":"3556860555840528"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NIO\">$蔚来(NIO)$ </a> 今天看不起蔚来 明天让你高攀不起!蔚来稳定2万+,乐道1万+, 年底股价必上30!","listText":"<a href=\"https://laohu8.com/S/NIO\">$蔚来(NIO)$ </a> 今天看不起蔚来 明天让你高攀不起!蔚来稳定2万+,乐道1万+, 年底股价必上30!","text":"$蔚来(NIO)$ 今天看不起蔚来 明天让你高攀不起!蔚来稳定2万+,乐道1万+, 年底股价必上30!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/313998368497744","isVote":1,"tweetType":1,"viewCount":1603,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3496875184649920","authorId":"3496875184649920","name":"阳光总在風雨后","avatar":"https://static.tigerbbs.com/520a456d0397b5810c0f55c66a1000d8","crmLevel":3,"crmLevelSwitch":0,"idStr":"3496875184649920","authorIdStr":"3496875184649920"},"content":"如果再次增发,蔚来股价顶多6、7刀左右,不可能像之前那样","text":"如果再次增发,蔚来股价顶多6、7刀左右,不可能像之前那样","html":"如果再次增发,蔚来股价顶多6、7刀左右,不可能像之前那样"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":312777169084656,"gmtCreate":1717395859817,"gmtModify":1717395860961,"author":{"id":"3556860555840528","authorId":"3556860555840528","name":"徐军1983","avatar":"https://static.tigerbbs.com/3c71435fdb1d7cf5b4939778f4e8ecfe","crmLevel":9,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3556860555840528","authorIdStr":"3556860555840528"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/FFIE\">$(FFIE)$ </a><v-v data-views=\"1\"></v-v> 重新起飞,破5美刀","listText":"<a href=\"https://laohu8.com/S/FFIE\">$(FFIE)$ </a><v-v data-views=\"1\"></v-v> 重新起飞,破5美刀","text":"$(FFIE)$ 重新起飞,破5美刀","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/312777169084656","isVote":1,"tweetType":1,"viewCount":1125,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":311889872916792,"gmtCreate":1717179125226,"gmtModify":1717179126499,"author":{"id":"3556860555840528","authorId":"3556860555840528","name":"徐军1983","avatar":"https://static.tigerbbs.com/3c71435fdb1d7cf5b4939778f4e8ecfe","crmLevel":9,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3556860555840528","authorIdStr":"3556860555840528"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NIO\">$(NIO)$ </a><v-v data-views=\"1\"></v-v> 看涨20美刀!","listText":"<a href=\"https://laohu8.com/S/NIO\">$(NIO)$ </a><v-v data-views=\"1\"></v-v> 看涨20美刀!","text":"$(NIO)$ 看涨20美刀!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/311889872916792","isVote":1,"tweetType":1,"viewCount":2162,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":311783469969664,"gmtCreate":1717145280803,"gmtModify":1717145282487,"author":{"id":"3556860555840528","authorId":"3556860555840528","name":"徐军1983","avatar":"https://static.tigerbbs.com/3c71435fdb1d7cf5b4939778f4e8ecfe","crmLevel":9,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3556860555840528","authorIdStr":"3556860555840528"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/FFIE\">$Faraday Future(FFIE)$ </a> 坚持持有,10美刀见!","listText":"<a href=\"https://laohu8.com/S/FFIE\">$Faraday Future(FFIE)$ </a> 坚持持有,10美刀见!","text":"$Faraday Future(FFIE)$ 坚持持有,10美刀见!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/311783469969664","isVote":1,"tweetType":1,"viewCount":659,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":311499201626240,"gmtCreate":1717075590810,"gmtModify":1717075592282,"author":{"id":"3556860555840528","authorId":"3556860555840528","name":"徐军1983","avatar":"https://static.tigerbbs.com/3c71435fdb1d7cf5b4939778f4e8ecfe","crmLevel":9,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3556860555840528","authorIdStr":"3556860555840528"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NIO\">$(NIO)$ </a><v-v data-views=\"1\"></v-v> 2024业绩爆表!看涨20元!","listText":"<a href=\"https://laohu8.com/S/NIO\">$(NIO)$ </a><v-v data-views=\"1\"></v-v> 2024业绩爆表!看涨20元!","text":"$(NIO)$ 2024业绩爆表!看涨20元!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/311499201626240","isVote":1,"tweetType":1,"viewCount":2115,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3550805207824943","authorId":"3550805207824943","name":"阿洋抄美股","avatar":"https://static.tigerbbs.com/0f88cfa5c3d4e483795484efeba1b7c6","crmLevel":7,"crmLevelSwitch":0,"idStr":"3550805207824943","authorIdStr":"3550805207824943"},"content":"你可能提前看到业绩?","text":"你可能提前看到业绩?","html":"你可能提前看到业绩?"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":306746351140960,"gmtCreate":1715923960459,"gmtModify":1715924100040,"author":{"id":"3556860555840528","authorId":"3556860555840528","name":"徐军1983","avatar":"https://static.tigerbbs.com/3c71435fdb1d7cf5b4939778f4e8ecfe","crmLevel":9,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3556860555840528","authorIdStr":"3556860555840528"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/FFIE\">$Faraday Future(FFIE)$ </a> FF的春天才刚开的,拿住了,10美金见!","listText":"<a href=\"https://laohu8.com/S/FFIE\">$Faraday Future(FFIE)$ </a> FF的春天才刚开的,拿住了,10美金见!","text":"$Faraday Future(FFIE)$ FF的春天才刚开的,拿住了,10美金见!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/306746351140960","isVote":1,"tweetType":1,"viewCount":740,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":306745901871104,"gmtCreate":1715923847553,"gmtModify":1715923970902,"author":{"id":"3556860555840528","authorId":"3556860555840528","name":"徐军1983","avatar":"https://static.tigerbbs.com/3c71435fdb1d7cf5b4939778f4e8ecfe","crmLevel":9,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3556860555840528","authorIdStr":"3556860555840528"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/FFIE\">$Faraday Future(FFIE)$ </a> ","listText":"<a href=\"https://laohu8.com/S/FFIE\">$Faraday Future(FFIE)$ </a> ","text":"$Faraday Future(FFIE)$","images":[{"img":"https://static.tigerbbs.com/fca1ccdaa2f0b4ef31e443006935ad7a","width":"372","height":"534"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/306745901871104","isVote":1,"tweetType":1,"viewCount":142,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":306493702172944,"gmtCreate":1715862136060,"gmtModify":1715864978202,"author":{"id":"3556860555840528","authorId":"3556860555840528","name":"徐军1983","avatar":"https://static.tigerbbs.com/3c71435fdb1d7cf5b4939778f4e8ecfe","crmLevel":9,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3556860555840528","authorIdStr":"3556860555840528"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/FFIE\">$Faraday Future(FFIE)$ </a> 10刀见","listText":"<a href=\"https://laohu8.com/S/FFIE\">$Faraday Future(FFIE)$ </a> 10刀见","text":"$Faraday Future(FFIE)$ 10刀见","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/306493702172944","isVote":1,"tweetType":1,"viewCount":872,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":306469961162968,"gmtCreate":1715856339257,"gmtModify":1715856613272,"author":{"id":"3556860555840528","authorId":"3556860555840528","name":"徐军1983","avatar":"https://static.tigerbbs.com/3c71435fdb1d7cf5b4939778f4e8ecfe","crmLevel":9,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3556860555840528","authorIdStr":"3556860555840528"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/FFIE\">$Faraday Future(FFIE)$ </a> 老美论坛上都在传,搞到10美金!","listText":"<a href=\"https://laohu8.com/S/FFIE\">$Faraday Future(FFIE)$ </a> 老美论坛上都在传,搞到10美金!","text":"$Faraday Future(FFIE)$ 老美论坛上都在传,搞到10美金!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":5,"repostSize":0,"link":"https://laohu8.com/post/306469961162968","isVote":1,"tweetType":1,"viewCount":3633,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"300246381537895","authorId":"300246381537895","name":"mencius","avatar":"https://static.tigerbbs.com/f81de94c89d642a1289ffe752eaae59c","crmLevel":4,"crmLevelSwitch":0,"idStr":"300246381537895","authorIdStr":"300246381537895"},"content":"确定退市了!还买进等着清零?","text":"确定退市了!还买进等着清零?","html":"确定退市了!还买进等着清零?"}],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":306469961162968,"gmtCreate":1715856339257,"gmtModify":1715856613272,"author":{"id":"3556860555840528","authorId":"3556860555840528","name":"徐军1983","avatar":"https://static.tigerbbs.com/3c71435fdb1d7cf5b4939778f4e8ecfe","crmLevel":9,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3556860555840528","authorIdStr":"3556860555840528"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/FFIE\">$Faraday Future(FFIE)$ </a> 老美论坛上都在传,搞到10美金!","listText":"<a href=\"https://laohu8.com/S/FFIE\">$Faraday Future(FFIE)$ </a> 老美论坛上都在传,搞到10美金!","text":"$Faraday Future(FFIE)$ 老美论坛上都在传,搞到10美金!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":5,"repostSize":0,"link":"https://laohu8.com/post/306469961162968","isVote":1,"tweetType":1,"viewCount":3633,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"300246381537895","authorId":"300246381537895","name":"mencius","avatar":"https://static.tigerbbs.com/f81de94c89d642a1289ffe752eaae59c","crmLevel":4,"crmLevelSwitch":0,"idStr":"300246381537895","authorIdStr":"300246381537895"},"content":"确定退市了!还买进等着清零?","text":"确定退市了!还买进等着清零?","html":"确定退市了!还买进等着清零?"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":313998368497744,"gmtCreate":1717680101499,"gmtModify":1717680103442,"author":{"id":"3556860555840528","authorId":"3556860555840528","name":"徐军1983","avatar":"https://static.tigerbbs.com/3c71435fdb1d7cf5b4939778f4e8ecfe","crmLevel":9,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3556860555840528","authorIdStr":"3556860555840528"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NIO\">$蔚来(NIO)$ </a> 今天看不起蔚来 明天让你高攀不起!蔚来稳定2万+,乐道1万+, 年底股价必上30!","listText":"<a href=\"https://laohu8.com/S/NIO\">$蔚来(NIO)$ </a> 今天看不起蔚来 明天让你高攀不起!蔚来稳定2万+,乐道1万+, 年底股价必上30!","text":"$蔚来(NIO)$ 今天看不起蔚来 明天让你高攀不起!蔚来稳定2万+,乐道1万+, 年底股价必上30!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/313998368497744","isVote":1,"tweetType":1,"viewCount":1603,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3496875184649920","authorId":"3496875184649920","name":"阳光总在風雨后","avatar":"https://static.tigerbbs.com/520a456d0397b5810c0f55c66a1000d8","crmLevel":3,"crmLevelSwitch":0,"idStr":"3496875184649920","authorIdStr":"3496875184649920"},"content":"如果再次增发,蔚来股价顶多6、7刀左右,不可能像之前那样","text":"如果再次增发,蔚来股价顶多6、7刀左右,不可能像之前那样","html":"如果再次增发,蔚来股价顶多6、7刀左右,不可能像之前那样"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":312777169084656,"gmtCreate":1717395859817,"gmtModify":1717395860961,"author":{"id":"3556860555840528","authorId":"3556860555840528","name":"徐军1983","avatar":"https://static.tigerbbs.com/3c71435fdb1d7cf5b4939778f4e8ecfe","crmLevel":9,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3556860555840528","authorIdStr":"3556860555840528"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/FFIE\">$(FFIE)$ </a><v-v data-views=\"1\"></v-v> 重新起飞,破5美刀","listText":"<a href=\"https://laohu8.com/S/FFIE\">$(FFIE)$ </a><v-v data-views=\"1\"></v-v> 重新起飞,破5美刀","text":"$(FFIE)$ 重新起飞,破5美刀","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/312777169084656","isVote":1,"tweetType":1,"viewCount":1125,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":311499201626240,"gmtCreate":1717075590810,"gmtModify":1717075592282,"author":{"id":"3556860555840528","authorId":"3556860555840528","name":"徐军1983","avatar":"https://static.tigerbbs.com/3c71435fdb1d7cf5b4939778f4e8ecfe","crmLevel":9,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3556860555840528","authorIdStr":"3556860555840528"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NIO\">$(NIO)$ </a><v-v data-views=\"1\"></v-v> 2024业绩爆表!看涨20元!","listText":"<a href=\"https://laohu8.com/S/NIO\">$(NIO)$ </a><v-v data-views=\"1\"></v-v> 2024业绩爆表!看涨20元!","text":"$(NIO)$ 2024业绩爆表!看涨20元!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/311499201626240","isVote":1,"tweetType":1,"viewCount":2115,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3550805207824943","authorId":"3550805207824943","name":"阿洋抄美股","avatar":"https://static.tigerbbs.com/0f88cfa5c3d4e483795484efeba1b7c6","crmLevel":7,"crmLevelSwitch":0,"idStr":"3550805207824943","authorIdStr":"3550805207824943"},"content":"你可能提前看到业绩?","text":"你可能提前看到业绩?","html":"你可能提前看到业绩?"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":306745901871104,"gmtCreate":1715923847553,"gmtModify":1715923970902,"author":{"id":"3556860555840528","authorId":"3556860555840528","name":"徐军1983","avatar":"https://static.tigerbbs.com/3c71435fdb1d7cf5b4939778f4e8ecfe","crmLevel":9,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3556860555840528","authorIdStr":"3556860555840528"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/FFIE\">$Faraday Future(FFIE)$ </a> ","listText":"<a href=\"https://laohu8.com/S/FFIE\">$Faraday Future(FFIE)$ </a> ","text":"$Faraday Future(FFIE)$","images":[{"img":"https://static.tigerbbs.com/fca1ccdaa2f0b4ef31e443006935ad7a","width":"372","height":"534"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/306745901871104","isVote":1,"tweetType":1,"viewCount":142,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":311783469969664,"gmtCreate":1717145280803,"gmtModify":1717145282487,"author":{"id":"3556860555840528","authorId":"3556860555840528","name":"徐军1983","avatar":"https://static.tigerbbs.com/3c71435fdb1d7cf5b4939778f4e8ecfe","crmLevel":9,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3556860555840528","authorIdStr":"3556860555840528"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/FFIE\">$Faraday Future(FFIE)$ </a> 坚持持有,10美刀见!","listText":"<a href=\"https://laohu8.com/S/FFIE\">$Faraday Future(FFIE)$ </a> 坚持持有,10美刀见!","text":"$Faraday Future(FFIE)$ 坚持持有,10美刀见!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/311783469969664","isVote":1,"tweetType":1,"viewCount":659,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":306746351140960,"gmtCreate":1715923960459,"gmtModify":1715924100040,"author":{"id":"3556860555840528","authorId":"3556860555840528","name":"徐军1983","avatar":"https://static.tigerbbs.com/3c71435fdb1d7cf5b4939778f4e8ecfe","crmLevel":9,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3556860555840528","authorIdStr":"3556860555840528"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/FFIE\">$Faraday Future(FFIE)$ </a> FF的春天才刚开的,拿住了,10美金见!","listText":"<a href=\"https://laohu8.com/S/FFIE\">$Faraday Future(FFIE)$ </a> FF的春天才刚开的,拿住了,10美金见!","text":"$Faraday Future(FFIE)$ FF的春天才刚开的,拿住了,10美金见!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/306746351140960","isVote":1,"tweetType":1,"viewCount":740,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":358521982963944,"gmtCreate":1728570071465,"gmtModify":1728570073289,"author":{"id":"3556860555840528","authorId":"3556860555840528","name":"徐军1983","avatar":"https://static.tigerbbs.com/3c71435fdb1d7cf5b4939778f4e8ecfe","crmLevel":9,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3556860555840528","authorIdStr":"3556860555840528"},"themes":[],"htmlText":"优秀","listText":"优秀","text":"优秀","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/358521982963944","repostId":"2474492713","repostType":2,"repost":{"id":"2474492713","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1728557104,"share":"https://www.laohu8.com/m/news/2474492713?lang=&edition=full","pubTime":"2024-10-10 18:45","market":"us","language":"zh","title":"辉瑞公司的抗癌药物组合在晚期研究中提高了总生存率","url":"https://stock-news.laohu8.com/highlight/detail?id=2474492713","media":"Reuters","summary":" 路透10月10日 - 辉瑞 周四称,在一项晚期研究中,其药物Talzenna和Xtandi的组合有助于延长一种晚期前列腺癌患者的生命。辉瑞公司说,与Xtandi单药相比,这种联合用药在转移性抗性前列腺癌 患者的总生存期方面有明显改善,无论是否存在基因突变。据辉瑞公司称,约有10%-20%的前列腺癌患者会在确诊后5到7年内患上mCRPC。辉瑞表示,它计划与全球卫生机构分享研究结果,以便更新Talzenna的标签。","content":"<html><body><p>((自动化翻译由路透提供,请见免责声明 ))</p><p> 路透10月10日 - <a href=\"https://laohu8.com/S/PFE\">辉瑞</a> 周四称,在一项晚期研究中,其药物Talzenna和Xtandi的组合有助于延长一种晚期前列腺癌患者的生命。</p><p>辉瑞公司说,与Xtandi单药相比,这种联合用药在转移性抗性前列腺癌(mCRPC) 患者的总生存期方面有明显改善,无论是否存在基因突变。 </p><p>总生存期是指患者在确诊或开始治疗后的生存时间。</p><p>mCRPC是一种癌症已扩散到身体其他部位的晚期疾病,通常预后较差。据辉瑞公司称,约有10%-20%的前列腺癌患者会在确诊后5到7年内患上mCRPC。 </p><p>Talzenna-Xtandi组合去年获得美国食品药品管理局批准 (link),用于治疗有一种基因突变的mCRPC患者。</p><p>辉瑞表示,它计划与全球卫生机构分享研究结果,以便更新Talzenna的标签。</p><p>美国食品和药物管理局去年还批准了 (link) <a href=\"https://laohu8.com/S/AZN\">阿斯利康</a>公司的Lynparza与激素疗法阿比特龙联用,治疗有一种基因突变的mCRPC患者。 </p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>辉瑞公司的抗癌药物组合在晚期研究中提高了总生存率</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n辉瑞公司的抗癌药物组合在晚期研究中提高了总生存率\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2024-10-10 18:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>((自动化翻译由路透提供,请见免责声明 ))</p><p> 路透10月10日 - <a href=\"https://laohu8.com/S/PFE\">辉瑞</a> 周四称,在一项晚期研究中,其药物Talzenna和Xtandi的组合有助于延长一种晚期前列腺癌患者的生命。</p><p>辉瑞公司说,与Xtandi单药相比,这种联合用药在转移性抗性前列腺癌(mCRPC) 患者的总生存期方面有明显改善,无论是否存在基因突变。 </p><p>总生存期是指患者在确诊或开始治疗后的生存时间。</p><p>mCRPC是一种癌症已扩散到身体其他部位的晚期疾病,通常预后较差。据辉瑞公司称,约有10%-20%的前列腺癌患者会在确诊后5到7年内患上mCRPC。 </p><p>Talzenna-Xtandi组合去年获得美国食品药品管理局批准 (link),用于治疗有一种基因突变的mCRPC患者。</p><p>辉瑞表示,它计划与全球卫生机构分享研究结果,以便更新Talzenna的标签。</p><p>美国食品和药物管理局去年还批准了 (link) <a href=\"https://laohu8.com/S/AZN\">阿斯利康</a>公司的Lynparza与激素疗法阿比特龙联用,治疗有一种基因突变的mCRPC患者。 </p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SG9999002232.USD":"Allianz Global High Payout USD","BK4007":"制药","LU0234572021.USD":"高盛美国核心股票组合Acc","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","PFE":"辉瑞","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","LU0058720904.USD":"联博国际健康护理基金A","SG9999002224.SGD":"Allianz Global High Payout SGD","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","BK4550":"红杉资本持仓","BK4588":"碎股","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","BK4568":"美国抗疫概念","LU0122379950.USD":"贝莱德世界健康科学A2","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","BK4581":"高盛持仓","SG9999001176.USD":"United Global Healthcare Acc USD","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY \"A\" (USD) ACC","LU1883839398.USD":"AMUNDI FUNDS INCOME OPPORTUNITIES \"A2\" (USD) ACC","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","BK4592":"伊斯兰概念","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","BK4533":"AQR资本管理(全球第二大对冲基金)"},"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2474492713","content_text":"((自动化翻译由路透提供,请见免责声明 )) 路透10月10日 - 辉瑞 周四称,在一项晚期研究中,其药物Talzenna和Xtandi的组合有助于延长一种晚期前列腺癌患者的生命。辉瑞公司说,与Xtandi单药相比,这种联合用药在转移性抗性前列腺癌(mCRPC) 患者的总生存期方面有明显改善,无论是否存在基因突变。 总生存期是指患者在确诊或开始治疗后的生存时间。mCRPC是一种癌症已扩散到身体其他部位的晚期疾病,通常预后较差。据辉瑞公司称,约有10%-20%的前列腺癌患者会在确诊后5到7年内患上mCRPC。 Talzenna-Xtandi组合去年获得美国食品药品管理局批准 (link),用于治疗有一种基因突变的mCRPC患者。辉瑞表示,它计划与全球卫生机构分享研究结果,以便更新Talzenna的标签。美国食品和药物管理局去年还批准了 (link) 阿斯利康公司的Lynparza与激素疗法阿比特龙联用,治疗有一种基因突变的mCRPC患者。","news_type":1},"isVote":1,"tweetType":1,"viewCount":88,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":355430951645464,"gmtCreate":1727777110090,"gmtModify":1727777111357,"author":{"id":"3556860555840528","authorId":"3556860555840528","name":"徐军1983","avatar":"https://static.tigerbbs.com/3c71435fdb1d7cf5b4939778f4e8ecfe","crmLevel":9,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3556860555840528","authorIdStr":"3556860555840528"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/XPEV\">$小鹏汽车(XPEV)$ </a> 重新站上50元!指日可待!","listText":"<a href=\"https://laohu8.com/S/XPEV\">$小鹏汽车(XPEV)$ </a> 重新站上50元!指日可待!","text":"$小鹏汽车(XPEV)$ 重新站上50元!指日可待!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/355430951645464","isVote":1,"tweetType":1,"viewCount":607,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":315808304271584,"gmtCreate":1718132577210,"gmtModify":1718132578485,"author":{"id":"3556860555840528","authorId":"3556860555840528","name":"徐军1983","avatar":"https://static.tigerbbs.com/3c71435fdb1d7cf5b4939778f4e8ecfe","crmLevel":9,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3556860555840528","authorIdStr":"3556860555840528"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AAPL\">$(AAPL)$ </a><v-v data-views=\"1\"></v-v> 继续涨 加油","listText":"<a href=\"https://laohu8.com/S/AAPL\">$(AAPL)$ </a><v-v data-views=\"1\"></v-v> 继续涨 加油","text":"$(AAPL)$ 继续涨 加油","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/315808304271584","isVote":1,"tweetType":1,"viewCount":420,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":311889872916792,"gmtCreate":1717179125226,"gmtModify":1717179126499,"author":{"id":"3556860555840528","authorId":"3556860555840528","name":"徐军1983","avatar":"https://static.tigerbbs.com/3c71435fdb1d7cf5b4939778f4e8ecfe","crmLevel":9,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3556860555840528","authorIdStr":"3556860555840528"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NIO\">$(NIO)$ </a><v-v data-views=\"1\"></v-v> 看涨20美刀!","listText":"<a href=\"https://laohu8.com/S/NIO\">$(NIO)$ </a><v-v data-views=\"1\"></v-v> 看涨20美刀!","text":"$(NIO)$ 看涨20美刀!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/311889872916792","isVote":1,"tweetType":1,"viewCount":2162,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":306493702172944,"gmtCreate":1715862136060,"gmtModify":1715864978202,"author":{"id":"3556860555840528","authorId":"3556860555840528","name":"徐军1983","avatar":"https://static.tigerbbs.com/3c71435fdb1d7cf5b4939778f4e8ecfe","crmLevel":9,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3556860555840528","authorIdStr":"3556860555840528"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/FFIE\">$Faraday Future(FFIE)$ </a> 10刀见","listText":"<a href=\"https://laohu8.com/S/FFIE\">$Faraday Future(FFIE)$ </a> 10刀见","text":"$Faraday Future(FFIE)$ 10刀见","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/306493702172944","isVote":1,"tweetType":1,"viewCount":872,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}